Glatiramer Acetate

Generic Name: Glatiramer Acetate

Indication: 用于治疗复发型多发性硬化症（MS/罕见病），包括成人临床孤立综合征、复发-缓解性疾病和活动性继发进行性疾病。

Clinical Trials

Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure

Phase 2

Completed

Conditions: Acute Decompensated Heart Failure
Cytokine Storm
Inflammatory Response
Heart Failure

Interventions: Drug: guideline directed medical therapy (GDMT)
Drug: Copaxone

First Posted Date: 2023-08-22

Last Posted Date: 2023-08-22

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 14

Registration Number: NCT06003972

Locations: 🇮🇱
Hadassah Ein Kerem medical center-hospital ,Cardiology Department, Jerusalem, Israel

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Phase 1

Active, not recruiting

Conditions: Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma
Basal Cell Carcinoma

Interventions: Drug: Copaxone

First Posted Date: 2019-06-11

Last Posted Date: 2023-05-19

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 10

Registration Number: NCT03982212

Locations: 🇺🇸
University of Kansas Cancer Center - CRC, Fairway, Kansas, United States
🇺🇸
The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Copaxone®

First Posted Date: 2015-07-16

Last Posted Date: 2021-12-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 861

Registration Number: NCT02499900

Locations: 🇺🇸
Teva Investigational Site 13483, Golden Valley, Minnesota, United States
🇧🇪
Teva Investigational Site 37063, Edegem, Belgium
🇦🇷
Teva Investigational Site 20062, Buenos Aires, Argentina

and more 94 locations

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

Phase 2

Terminated

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Plovamer acetate 0.5 milligram (mg)
Drug: Plovamer acetate 3 mg
Drug: Plovamer acetate 10 mg
Drug: Plovamer acetate 20 mg
Drug: Copaxone 20 mg

First Posted Date: 2013-10-16

Last Posted Date: 2016-05-11

Lead Sponsor: EMD Serono

Target Recruit Count: 255

Registration Number: NCT01963611

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States
🇬🇧
Research site, Stoke on Trent, United Kingdom

Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure

Phase 3

Conditions: Glaucoma, Angle-closure, Primary, Acute

Interventions: Drug: Placebo (buffered normal saline w/v)
Drug: Copaxone

First Posted Date: 2013-09-05

Last Posted Date: 2013-09-06

Lead Sponsor: Singapore Eye Research Institute

Target Recruit Count: 196

Registration Number: NCT01936129

Locations: 🇸🇬
Singapore Eye Research Institute, Singapore, Singapore

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Copaxone

First Posted Date: 2009-07-10

Last Posted Date: 2021-03-19

Lead Sponsor: University at Buffalo

Target Recruit Count: 12

Registration Number: NCT00937157

Locations: 🇺🇸
Jacobs Neurological Institute, Buffalo, New York, United States

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

Phase 1

Suspended

Conditions: Dry Age Related Macular Degeneration

Interventions: Drug: Copaxone Injection

First Posted Date: 2007-10-10

Last Posted Date: 2013-05-03

Lead Sponsor: The New York Eye & Ear Infirmary

Target Recruit Count: 15

Registration Number: NCT00541333

Locations: 🇺🇸
New York Eye and Ear Infirmary, New York, New York, United States

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis
Low Bone Density

Interventions: Drug: Interferon-beta 1a
Drug: Copaxone
Drug: Interferon-beta 1b

First Posted Date: 2007-06-25

Last Posted Date: 2014-01-22

Lead Sponsor: Nancy Hammond, MD

Target Recruit Count: 60

Registration Number: NCT00490906

Locations: 🇺🇸
General Clinical Research Center, Kansas City, Kansas, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Copaxone in Age Related Macular Degeneration

Phase 2

Conditions: Macular Degeneration

First Posted Date: 2007-04-27

Last Posted Date: 2007-04-27

Lead Sponsor: Kaplan Medical Center

Target Recruit Count: 30

Registration Number: NCT00466076

Locations: 🇮🇱
Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

Phase 2

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Estriol
Drug: Copaxone

First Posted Date: 2007-03-23

Last Posted Date: 2016-06-16

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 158

Registration Number: NCT00451204

Locations: 🇺🇸
Western Institute for Biomedical Research, Salt Lake City, Utah, United States
🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸
Dartmouth Medical School, Lebanon, New Hampshire, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy